STOCK TITAN

Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Kezar Life Sciences, Inc. (Nasdaq: KZR), a biotechnology firm focused on immune-mediated and oncologic disorders, will have its Chief Medical Officer, Noreen Roth Henig, participate in the Kidney Disease/Fibrosis Panel at the Cowen 42nd Annual Health Care Conference. The event is scheduled for Wednesday, March 9, 2022, at 2:10 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. Kezar is developing innovative therapies such as KZR-616 for various chronic diseases and KZR-261 for cancer treatment.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Kidney Disease/Fibrosis Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Wednesday, March 9, 2022, at 2:10 p.m. ET.

A live webcast of the panel will be available on the “Events & Presentations” section of the Company’s website at https://www.kezarlifesciences.com/investors/news-events/ir-calendar. A replay will be available on the Kezar website for 90 days following the event.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. This asset also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

Gitanjali Jain

Vice President, Investor Relations and External Affairs

650-269-7523

gjain@kezarbio.com

Liza Sullivan

Argot Partners

617-340-6073

kezar@argotpartners.com

Source: Kezar Life Sciences, Inc.

FAQ

What is the date and time of Kezar Life Sciences' participation in the Cowen 42nd Annual Health Care Conference?

Kezar Life Sciences' Chief Medical Officer will participate on Wednesday, March 9, 2022, at 2:10 p.m. ET.

How can I watch the Kezar Life Sciences panel discussion at the Cowen Conference?

You can watch the live webcast of the panel on the 'Events & Presentations' section of the Kezar Life Sciences website.

What are the main drug candidates being developed by Kezar Life Sciences?

Kezar Life Sciences is developing KZR-616 for immune-mediated diseases and KZR-261 for cancer treatment.

What types of disorders does Kezar Life Sciences focus on?

Kezar Life Sciences focuses on discovering treatments for immune-mediated and oncologic disorders.

How long will the replay of the Kezar Life Sciences panel be available?

The replay of the panel will be available for 90 days following the event.

Kezar Life Sciences, Inc.

NASDAQ:KZR

KZR Rankings

KZR Latest News

KZR Stock Data

47.21M
6.02M
14.8%
63.9%
2.44%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO